Skip to main content
. 2013 Aug;20(8):1283–1290. doi: 10.1128/CVI.00213-13

Table 2.

Fold changes in subclusters of patients for 10 selected immunomodulatorsa

Immunomodulator Fold change
HiLa vs baseline (A) LiMa vs baseline (B) Difference (A − B)
IP-10 (CXCL10) 9.0 3.8 5.2
MIG (CXCL9) 6.6 3.8 2.8
IL-18 3.8 2.2 1.6
IL-6 4.1 3.6 0.5
IL-16 (2.7) (2.9) (0.2)
PDGF-BB 2.8 2.3 0.5
IFN-γ 2.3 1.7 0.6
GROα (CXCL1) 3.2 0.0 3.2
G-CSF 1.8 1.6 0.2
VEGF 14.2 6.5 8.1
a

Immunomodulators (10 analytes selected from 50) in the two main patient subclusters with respect to analyte assay baselines (see Materials and Methods) were determined by using multivariate analysis. Immunomodulators in the HiLa cluster altered by about 2-fold (P value of <0.01) compared to the LiMa cluster are shaded. Negative fold changes are given in parentheses.